CJC-1295 DAC

The defining clinical study of CJC-1295 DAC was a randomized, placebo-controlled trial in healthy adults that established its pharmacokinetic and pharmacodynamic profile (1). A single subcutaneous injection produced dose-dependent increases in plasma growth hormone of two- to ten-fold lasting six days or more, and IGF-1 increases of 1.5- to three-fold lasting nine to eleven days. The estimated half-life of the peptide itself was 5.8 to 8.1 days. With weekly or biweekly dosing, IGF-1 levels remained elevated above baseline for up to 28 days, suggesting a cumulative effect.

The mechanism behind this prolonged action was characterized in earlier preclinical work that identified CJC-1295 as a tetrasubstituted GHRH(1-29) analog (2). The maleimide group at the C-terminus reacts with the free thiol on Cys34 of serum albumin, forming a covalent bond within minutes of administration. Western blot analysis confirmed CJC-1295 still circulating attached to albumin beyond 24 hours, with detection in plasma extending past 72 hours. The albumin-bound complex retains the ability to activate pituitary GHRH receptors while being protected from the enzymes that normally chew up free peptides.

One concern with any continuous GHRH stimulation is whether it would flatten the body's natural pulsatile pattern of GH release — pulses that appear to matter for many of the hormone's physiological effects. A dedicated clinical study in healthy men addressed this directly by sampling blood every 20 minutes over a 12-hour overnight period before and one week after a single CJC-1295 DAC injection (3).

The results were reassuring: GH pulse frequency and magnitude were unchanged. What did shift were the trough levels — the baseline between pulses — which rose 7.5-fold. Mean GH levels increased about 46%, and IGF-1 rose about 45%. In other words, the peptide appears to lift the floor rather than flatten the pattern, preserving the rhythmic signaling thought to be biologically important while still driving meaningful increases in downstream IGF-1.

Preclinical work in models of GHRH deficiency reinforced the dosing implications: once-daily administration normalized growth and body composition, while less frequent dosing produced only partial effects (4). This suggests the peptide's long half-life enables flexible dosing schedules but that more frequent administration produces more complete signaling.

Interest in CJC-1295 DAC within sports medicine and recovery contexts stems from the well-established effects of the GH/IGF-1 axis on muscle, connective tissue, and bone. Recent reviews of injectable peptide therapy in orthopaedics have included CJC-1295 — often paired with ipamorelin, a complementary GH secretagogue — among the growth-hormone-releasing peptides being explored for tissue repair and recovery (5, 6).

The proposed mechanism involves activation of IGF-1 signaling and satellite cell repair pathways relevant to muscle regeneration (6). In preclinical models of glucocorticoid-induced muscle loss, CJC-1295 combined with ipamorelin improved maximum tetanic tension — a measure of muscle force production (5). However, these orthopaedic-specific applications remain preclinical, and the reviewers note that dosing, frequency, and clinical efficacy for musculoskeletal conditions are not yet established. The strongest direct human evidence remains the original pharmacokinetic trials documenting sustained GH and IGF-1 elevation, with downstream functional outcomes still being characterized.

Reported side effects in the published clinical trials have been minimal. In the randomized controlled studies of healthy adults, no serious adverse reactions were reported across single and multiple dosing regimens, with the peptide described as well tolerated particularly at doses of 30 to 60 µg/kg (1, 3). Anecdotally, users report transient effects common to GH-releasing peptides — injection site reactions, mild water retention, occasional tingling in the hands, and head-fullness in the first days of use — typically resolving with continued use or dose adjustment.

The body of CJC-1295 DAC evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety has not been formally characterized.

CJC-1295 is classified as a prohibited substance under Section S2 of the World Anti-Doping Agency's list, relevant context for competitive athletes.